Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YGX2
- Development stage
- Preclinical
- Lead developer
- Youngene Therapeutics
- Modality
- Small Molecules
01
Overview
YGX2 is a small molecule drug candidate developed by Youngene Therapeutics. It is currently in preclinical development and has been investigated for the treatment of gout and nonalcoholic steatohepatitis (NASH). The drug is being explored for use in therapeutic areas including congenital disorders, digestive system disorders, and endocrinology/metabolic diseases. As of the latest update, no detailed mechanism of action or molecular target has been disclosed publicly[1].
Beyond the preview
Go deeper on YGX2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YGX2.